F-X Mahon

1.5k total citations
26 papers, 682 citations indexed

About

F-X Mahon is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, F-X Mahon has authored 26 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 11 papers in Genetics and 10 papers in Rheumatology. Recurrent topics in F-X Mahon's work include Chronic Myeloid Leukemia Treatments (20 papers), Eosinophilic Disorders and Syndromes (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). F-X Mahon is often cited by papers focused on Chronic Myeloid Leukemia Treatments (20 papers), Eosinophilic Disorders and Syndromes (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). F-X Mahon collaborates with scholars based in France, United States and Germany. F-X Mahon's co-authors include Josy Reiffers, Françis Belloc, Jean Ripoche, Claude Preudhomme, Valérie Lagarde, Christophe F. Grosset, Catherine Roche‐Lestienne, JV Melo, Michel Tulliez and JM Goldman and has published in prestigious journals such as Blood, Oncogene and Annals of Oncology.

In The Last Decade

F-X Mahon

26 papers receiving 668 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F-X Mahon France 15 496 370 230 180 91 26 682
Allen Lin United States 9 736 1.5× 393 1.1× 166 0.7× 338 1.9× 188 2.1× 18 957
AM Gewirtz United States 6 448 0.9× 242 0.7× 89 0.4× 279 1.6× 115 1.3× 7 664
Samuel B. Luty United States 9 311 0.6× 313 0.8× 133 0.6× 193 1.1× 53 0.6× 13 500
Matthew S. Zabriskie United States 9 416 0.8× 301 0.8× 113 0.5× 307 1.7× 170 1.9× 24 720
Chung Hoow Kok Australia 17 454 0.9× 245 0.7× 90 0.4× 338 1.9× 153 1.7× 68 800
Helena Ågerstam Sweden 11 362 0.7× 156 0.4× 91 0.4× 182 1.0× 155 1.7× 20 574
Nils Hansen Sweden 11 340 0.7× 192 0.5× 100 0.4× 182 1.0× 149 1.6× 24 584
Simona Luatti Italy 12 703 1.4× 622 1.7× 444 1.9× 76 0.4× 56 0.6× 24 788
Mauro Nanni Italy 16 456 0.9× 294 0.8× 97 0.4× 402 2.2× 86 0.9× 43 804
Camelia Iancu‐Rubin United States 15 342 0.7× 281 0.8× 85 0.4× 292 1.6× 149 1.6× 36 655

Countries citing papers authored by F-X Mahon

Since Specialization
Citations

This map shows the geographic impact of F-X Mahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F-X Mahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F-X Mahon more than expected).

Fields of papers citing papers by F-X Mahon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F-X Mahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F-X Mahon. The network helps show where F-X Mahon may publish in the future.

Co-authorship network of co-authors of F-X Mahon

This figure shows the co-authorship network connecting the top 25 collaborators of F-X Mahon. A scholar is included among the top collaborators of F-X Mahon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F-X Mahon. F-X Mahon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hughes, Timothy P., Brian Leber, Francisco Cervantes, et al.. (2017). Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 31(11). 2529–2531. 31 indexed citations
2.
Sticht, Carsten, Markus Pfirrmann, Daniel Nowak, et al.. (2017). The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia. Annals of Oncology. 28. v367–v367. 1 indexed citations
3.
Mahon, F-X, Isabelle Lamrissi‐Garcia, Isabelle Moranvillier, et al.. (2016). Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells. Leukemia. 31(1). 65–74. 11 indexed citations
4.
5.
Réa, Delphine, Gabriel Étienne, Franck E. Nicolini, et al.. (2012). First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 26(10). 2254–2259. 30 indexed citations
6.
Hétuin, Dominique, Céline Berthon, Xavier Dezitter, et al.. (2011). GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells. Oncogene. 31(11). 1419–1430. 40 indexed citations
7.
Gamas, Pascal, Sandrine Marchetti, Alexandre Puissant, et al.. (2009). Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. Leukemia. 23(8). 1500–1506. 20 indexed citations
8.
Belloc, Françis, M. Garcia, Estelle Guérin, et al.. (2009). The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells. Leukemia. 23(4). 679–685. 35 indexed citations
9.
10.
Hasford, Joerg, Markus Pfirrmann, R. Hehlmann, et al.. (2003). Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy. Seminars in Hematology. 40(1). 4–12. 5 indexed citations
11.
Mahon, F-X, et al.. (2002). Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia. 16(12). 2349–2357. 67 indexed citations
12.
Tabrizi, Reza, F-X Mahon, Pascale Cony Makhoul, et al.. (2002). Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. Leukemia. 16(6). 1154–1159. 7 indexed citations
13.
Solanilla, A., Christophe F. Grosset, Pascale Duchez, et al.. (2000). Differential effect of interferon α on chronic myelogenous leukaemia and normal haematopoietic progenitors in a stromal cell co‐culture context: role of the flt3 ligand. British Journal of Haematology. 109(2). 382–387. 3 indexed citations
14.
Solanilla, A., Christophe F. Grosset, Claudie Lemercier, et al.. (2000). Expression of Flt3-ligand by the endothelial cell. Leukemia. 14(1). 153–162. 51 indexed citations
15.
Pigneux, Arnaud, C. Fabères, JM Boiron, et al.. (1999). Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience. Bone Marrow Transplantation. 24(3). 265–270. 8 indexed citations
16.
Pigneux, Arnaud, F-X Mahon, & Josy Reiffers. (1999). Autologous peripheral blood stem cell transplantation for chronic myelocytic leukaemia, using unmanipulated grafts. Best Practice & Research Clinical Haematology. 12(1-2). 193–198. 1 indexed citations
17.
Mazurier, Frédéric, François Moreau‐Gaudry, Véronique Maguer‐Satta, et al.. (1998). Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein. Gene Therapy. 5(4). 556–562. 15 indexed citations
18.
Jaźwiec, Bożena, A. Solanilla, Christophe F. Grosset, et al.. (1998). Endothelial cell support of hematopoiesis is differentially altered by IL-1 and glucocorticoids. Leukemia. 12(8). 1210–1220. 30 indexed citations
19.
Mahon, F-X, Hikmat Chahine, Cécile Barbot, et al.. (1997). All-trans retinoic acid potentiates the inhibitory effects of interferon α on chronic myeloid leukemia progenitors in vitro. Leukemia. 11(5). 667–673. 13 indexed citations
20.
Moreau‐Gaudry, François, Cécile Barbot, Frédéric Mazurier, et al.. (1996). Correction of the enzyme deficit of bone marrow cells in congenital erythropoietic porphyria by retroviral gene transfer. PubMed. 38(2). 217–220. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Allen Lin Breakdown of academic impact, for papers by AM Gewirtz Breakdown of academic impact, for papers by Samuel B. Luty Breakdown of academic impact, for papers by Matthew S. Zabriskie Breakdown of academic impact, for papers by Chung Hoow Kok Breakdown of academic impact, for papers by Helena Ågerstam Breakdown of academic impact, for papers by Nils Hansen Breakdown of academic impact, for papers by Simona Luatti Breakdown of academic impact, for papers by Mauro Nanni Breakdown of academic impact, for papers by Camelia Iancu‐Rubin
Rankless by CCL
2026